Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Metadata
Title
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Author
Kaj Blennow
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 2/2004
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1602/neurorx.1.2.213

Other articles of this Issue 2/2004

Neurotherapeutics 2/2004 Go to the issue

OriginalPaper

Measures and markers in Amyotrophic Lateral Sclerosis

OriginalPaper

Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis

OriginalPaper

Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease

OriginalPaper

Molecular neuroimaging in Alzheimer’s disease

OriginalPaper

Biomarkers: Potential uses and limitations

Editorial

Biomarkers and surrogates